Retrospective Review of Single Centre’s Experience of the Side Effects Reported by Patients Receiving Everolimus and the Potential Implications Relating to Patient Monitoring and Education

#1525

Introduction: Everolimus, an mTOR inhibitor, is a recommended therapy for patients with pancreatic neuroendocrine tumours. It has recognised toxicity profile.

Aim(s): To identify side-effects reported in clinic which would guide both patient management and teaching.

Materials and methods: A retrospective review of patients receiving Everolimus between 2011 to 2015.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Davies P,

Keywords: everolimus, patient education, side effects,